Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NK1 homeobox 2 (NKX1-2) is a DNA-binding transcription factor belonging to the homeobox protein family. It functions primarily as a transcriptional repressor, regulating gene expression during cell differentiation and early development. NKX1-2 is predicted to act as a Wnt/beta-catenin effector and may control pluripotency and preimplantation development, particularly in the central nervous system. Its expression is mainly nuclear, and it belongs to a family of homeobox genes that includes several paralogs such as NKX1-1. NKX1-2 is not commonly recognized as a druggable or therapeutic target and does not have known drug interactions, mechanisms of action, or established biomarker or safety concern roles. It is a gene regulatory transcription factor essential for developmental processes, especially in the central nervous system, but is not directly linked to particular diseases or relevant to pharmacological interventions in current literature.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NK1 homeobox 2 (NKX1-2).